As we continue our journey to learn more about how companies are exploiting cool new technologies around artificial intelligence, machine learning and deep learning, this time we explore some concepts around RNA therapies and find out how a biotech is making strides in this niche.

Imagine being able to analyse massive biological datasets to derive novel targets and therapeutics?

The open star cluster NGC 330 Source: NASA

Perhaps one of the more refreshing aspects which has struck me from the AI/ML niche so far is how eager, dynamic, and enthusiastic the CEOs have been to talk about what they are doing, why it’s exciting, what challenges need to be addressed, and where they are planning to go.

Today’s CEO interview is another great example of this genre.

While their current pipeline examples are non-oncology focused, if there are improvements in delivery technology then they may have future applications in cancer research for them too…

BSB subscribers can learn more about our latest interview in the AI/deep learning niche – you can read all about it by logging in or click to access our ongoing oncology coverage.

This content is restricted to subscribers

Posted by